SAVIOR LIFETEC CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.2 TWD | -2.08% |
|
+1.44% | -5.57% |
| Sales 2022 | 1.27B 38.88M 3.24B | Sales 2023 | 1.05B 32.26M 2.69B | Capitalization | 7.13B 219M 18.25B |
|---|---|---|---|---|---|
| Net income 2022 | 36M 1.11M 92.2M | Net income 2023 | 30M 921K 76.83M | EV / Sales 2022 | 5.78 x |
| Net cash position 2022 | 549M 16.85M 1.41B | Net cash position 2023 | 1.07B 32.77M 2.73B | EV / Sales 2023 | 5.77 x |
| P/E ratio 2022 |
225
x | P/E ratio 2023 |
240
x | Employees | 384 |
| Yield 2022 |
0.42% | Yield 2023 |
-
| Free-Float | 84.7% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -2.08% | ||
| 1 week | +1.44% | ||
| Current month | +8.44% | ||
| 1 month | +8.72% | ||
| 3 months | +5.74% | ||
| 6 months | +14.59% | ||
| Current year | -5.57% |
1 week
21.00
22.50
1 month
19.5022.50
Current year
18.1024.20
1 year
16.7527.00
3 years
15.4031.29
5 years
15.4042.73
10 years
14.3454.74
| Managers | Title | Age | Since |
|---|---|---|---|
Yung-Fa Chen
CEO | Chief Executive Officer | - | 03/18/03 |
Man Chin Ku
CHM | Chairman | - | 03/13/03 |
Emma Wang
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Man Chin Ku
CHM | Chairman | - | 03/13/03 |
| Director/Board Member | - | 24/10/24 | |
Chia Yue Wu
BRD | Director/Board Member | - | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 21.2 | -2.08% | 1,967,808 |
| 25/24/25 | 21.65 | -1.81% | 2,065,087 |
| 24/24/24 | 22.05 | +0.68% | 2,842,643 |
| 23/24/23 | 21.9 | +1.15% | 4,084,091 |
| 22/24/22 | 21.65 | +3.59% | 4,119,372 |
End-of-day quote Taipei Exchange, April 26, 2024
More quotes
SAVIOR LIFETEC CORPORATION is a Taiwan-based company principally engaged in the development, manufacture and distribution of antibiotic bulk pharmaceutical chemicals and intermediates. The Companyâs products portfolio mainly consists of Meropenem and Imipenem/Cilastatin, Meropenem as well as Ertapenem, among others, which are used as spectrum antibiotics. In addition, it is involved in the provision of APIs intermediates as well as bio-pharmaceutical technology services. The Company distributes its products to Europe, the Americas, Asia and other markets.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -5.57% | 206M | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- 4167 Stock
